JP2006516639A5 - - Google Patents

Info

Publication number

JP2006516639A5

JP2006516639A5 JP2006503233A JP2006503233A JP2006516639A5 JP 2006516639 A5 JP2006516639 A5 JP 2006516639A5 JP 2006503233 A JP2006503233 A JP 2006503233A JP 2006503233 A JP2006503233 A JP 2006503233A JP 2006516639 A5 JP2006516639 A5 JP 2006516639A5

Authority

JP

Japan

Prior art keywords

fragment

use according

carrier molecule

composition

adjuvant

Prior art date

2004-01-31

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000012634 fragment Substances 0.000 claims 61
• 239000000203 mixture Substances 0.000 claims 19
• 239000002671 adjuvant Substances 0.000 claims 17
• 239000003814 drug Substances 0.000 claims 11
• 125000003275 alpha amino acid group Chemical group 0.000 claims 10
• 201000010099 disease Diseases 0.000 claims 7
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
• 239000004568 cement Substances 0.000 claims 5
• 230000028993 immune response Effects 0.000 claims 5
• 102000040430 polynucleotide Human genes 0.000 claims 5
• 108091033319 polynucleotide Proteins 0.000 claims 5
• 239000002157 polynucleotide Substances 0.000 claims 5
• 208000024827 Alzheimer disease Diseases 0.000 claims 3
• OYRVWOGRRQDEQH-MLVLNPCWSA-N Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Leu Chemical compound C([C@@H](C(=O)N[C@@H](C(C)CC)C(=O)NCC(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](C(C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](N)CCC(N)=O)C(C)CC)C1=CC=CC=C1 OYRVWOGRRQDEQH-MLVLNPCWSA-N 0.000 claims 3
• 239000002131 composite material Substances 0.000 claims 3
• 210000004898 n-terminal fragment Anatomy 0.000 claims 3
• 229920001184 polypeptide Polymers 0.000 claims 3
• 230000002265 prevention Effects 0.000 claims 3
• 102000004196 processed proteins & peptides Human genes 0.000 claims 3
• 108090000765 processed proteins & peptides Proteins 0.000 claims 3
• 208000037259 Amyloid Plaque Diseases 0.000 claims 2
• 102000016607 Diphtheria Toxin Human genes 0.000 claims 2
• 108010053187 Diphtheria Toxin Proteins 0.000 claims 2
• 229940037003 alum Drugs 0.000 claims 2
• 230000015572 biosynthetic process Effects 0.000 claims 2
• 210000004556 brain Anatomy 0.000 claims 2
• 238000010382 chemical cross-linking Methods 0.000 claims 2
• 238000004519 manufacturing process Methods 0.000 claims 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 2
• 230000000069 prophylactic effect Effects 0.000 claims 2
• 125000006850 spacer group Chemical group 0.000 claims 2
• 208000024891 symptom Diseases 0.000 claims 2
• 101150056293 AJUBA gene Proteins 0.000 claims 1
• 208000000340 Alzheimer disease type 1 Diseases 0.000 claims 1
• 208000028698 Cognitive impairment Diseases 0.000 claims 1
• 229920000742 Cotton Polymers 0.000 claims 1
• 230000005867 T cell response Effects 0.000 claims 1
• 210000003719 b-lymphocyte Anatomy 0.000 claims 1
• 210000004369 blood Anatomy 0.000 claims 1
• 239000008280 blood Substances 0.000 claims 1
• 230000036755 cellular response Effects 0.000 claims 1
• 208000010877 cognitive disease Diseases 0.000 claims 1
• 230000002068 genetic effect Effects 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 claims 1
• 238000007918 intramuscular administration Methods 0.000 claims 1
• 238000007912 intraperitoneal administration Methods 0.000 claims 1
• 238000001990 intravenous administration Methods 0.000 claims 1
• 238000000034 method Methods 0.000 claims 1
• 238000012544 monitoring process Methods 0.000 claims 1
• 238000007920 subcutaneous administration Methods 0.000 claims 1
• 239000004094 surface-active agent Substances 0.000 claims 1
• 238000011200 topical administration Methods 0.000 claims 1
• 230000000699 topical effect Effects 0.000 claims 1